Clinical Trial: Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT

U.S., Nov. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07909733) titled 'Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT' on Oct. 27.

Brief Summary: The purpose of this clinical trial is to learn if imetelstat is safe to use in participants with high-risk myeloid malignancies who have received an allogenic hematologic stem cell transplantation (allo-SCT).

Participants will receive imetelstat by intravenous infusion once every 28 days for up to one year.

Study Start Date: Feb., 2027

Study Type: INTERVENTIONAL

Condition: High-risk Myeloid Malignancy Allogenic Stem Cell Transplantation Acute Myeloid Leukemia (AML) Chronic Myeloid Leukemia (CML) Primary M...